<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707118</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-30</org_study_id>
    <nct_id>NCT04707118</nct_id>
  </id_info>
  <brief_title>Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy</brief_title>
  <official_title>Peritoneal Perfusion Chemotherapy Combined With Gemcitabine and Albumin Binding Paclitaxel Versus Gemcitabine and Albumin Binding Paclitaxel in the Treatment of Advanced Pancreatic Cancer With Intraperitoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the existence of malignant ascites in patients with advanced pancreatic cancer, we&#xD;
      put forward the heat abdominal cavity perfusion chemotherapy combined albumin paclitaxel and&#xD;
      gemcitabine compared with albumin paclitaxel and gemcitabine prospective clinical study, to&#xD;
      assess abdominal albumin hot perfusion chemotherapy combined control of ascites and taxol in&#xD;
      improving patients' quality of life, survival, exploring the feasibility of celiac hot&#xD;
      perfusion chemotherapy combined albumin paclitaxel and side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 23, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ascites control</measure>
    <time_frame>4 weeks</time_frame>
    <description>The change of abdominal volume of subjects from enrollment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Thermal perfusion cisplatin+Nab-paclitaxel+GEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nab-paclitaxel+GEM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin+Nab-paclitaxel+GEM</intervention_name>
    <description>Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles</description>
    <arm_group_label>Thermal perfusion cisplatin+Nab-paclitaxel+GEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel+GEM</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles</description>
    <arm_group_label>Nab-paclitaxel+GEM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participate voluntarily and sign informed consent;&#xD;
&#xD;
          -  Age ≥18 years old and ≤80 years old, regardless of gender;&#xD;
&#xD;
          -  Physical condition ECOG 0 ~ 2;&#xD;
&#xD;
          -  The diagnosis of pancreatic adenocarcinoma was confirmed by pathology;&#xD;
&#xD;
          -  Peritoneal metastasis was confirmed by ascites cytology, or was pathologically&#xD;
             confirmed by surgical exploration and biopsy;&#xD;
&#xD;
          -  Expected survival ≥3 months;&#xD;
&#xD;
          -  No serious abnormal blood system, heart and lung function and immune deficiency (refer&#xD;
             to respective standards);&#xD;
&#xD;
          -  Blood routine indicators: white blood cell (WBC) ≥3 × 109/L;Absolute count of&#xD;
             neutrophils (ANC) ≥1.5 × 109/L;Platelet (PLT) ≥100 × 109/L;Hemoglobin (Hgb) ≥9 g/dL;&#xD;
&#xD;
          -  Blood biochemical indexes: AST (SGOT) and ALT (SGPT) ≤2.5 × upper limit of normal&#xD;
             value (ULN);Total bilirubin (TBIL) ≤ULN;Serum creatinine (CRE) ≤1.5 × ULN;&#xD;
&#xD;
          -  Coagulation function: Prothrombin time (PT), international standard ratio (INR) ≤1.5 ×&#xD;
             ULN;&#xD;
&#xD;
          -  Comply with the study visit plan and other program requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accompanied by other systemic malignant tumors;&#xD;
&#xD;
          -  Received any form of anti-tumor therapy, including interventional chemoembolization,&#xD;
             ablation, radiotherapy, chemotherapy, tumor palliative resection and molecular&#xD;
             targeted therapy;&#xD;
&#xD;
          -  Used any other study drugs within 5 weeks before enrollment;&#xD;
&#xD;
          -  Central nervous system diseases, mental diseases, unstable angina pectoris, congestive&#xD;
             heart failure, severe arrhythmia and other serious diseases that cannot be controlled;&#xD;
&#xD;
          -  Uncontrolled infection, bleeding, pancreatic leakage, bile leakage, or other&#xD;
             postoperative complications during baseline examination;Acute and chronic metabolic&#xD;
             acidosis (including ketoacidosis and lactic acidosis) has not been corrected.&#xD;
&#xD;
          -  A history of allergy to study drugs or similar structured drugs;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Any conditions, including serious medical risk factors, medical conditions, and&#xD;
             laboratory abnormalities, that may impair patient safety or the integrity of research&#xD;
             data;&#xD;
&#xD;
          -  Intestinal obstruction, extensive adhesion in the peritoneal cavity, abdominal&#xD;
             inflammation, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xianjun YU, PhD</last_name>
    <phone>18019112906</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Sahnghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianjun Yu, Phd</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>President of Shanghai Pancreatic Cancer Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

